Skip to main content
Top
Published in: Pediatric Nephrology 7/2017

Open Access 01-07-2017 | Brief Report

Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2

Authors: Kioa L. Wijnsma, Anne M. Schijvens, John W. A. Rossen, A. M. D. (Mirjam) Kooistra-Smid, Michiel F. Schreuder, Nicole C. A. J. van de Kar

Published in: Pediatric Nephrology | Issue 7/2017

Login to get access

Abstract

Background

Hemolytic uremic syndrome (HUS) is one of the most common causes of acute renal failure in children, with the majority of cases caused by an infection with Shiga toxin-producing Escherichia coli (STEC). Whereas O157 is still the predominant STEC serotype, non-O157 serotypes are increasingly associated with STEC-HUS. However, little is known about this emerging and highly diverse group of non-O157 serotypes. With supportive therapy, STEC-HUS is often self-limiting, with occurrence of chronic sequelae in just a small proportion of patients.

Case diagnosis/treatment

In this case report, we describe a 16-month-old boy with a highly severe and atypical presentation of STEC-HUS. Despite the presentation with multi-organ failure and extensive involvement of central nervous system due to extensive thrombotic microangiopathy (suggestive of atypical HUS), fecal diagnostics revealed an infection with the rare serotype: shiga toxin 2d-producing STEC O80:H2.

Conclusions

This report underlines the importance of STEC diagnostic tests in all children with HUS, including those with an atypical presentation, and emphasizes the importance of molecular and serotyping assays to estimate the virulence of an STEC strain.
Literature
1.
2.
go back to reference Espie E, Grimont F, Mariani-Kurkdjian P, Bouvet P, Haeghebaert S, Filliol I, Loirat C, Decludt B, Minh NN, Vaillant V, de Valk H (2008) Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 Shiga toxin-producing Escherichia coli infections in France, 1996–2006. Pediatr Infect Dis J 27:595–601CrossRefPubMed Espie E, Grimont F, Mariani-Kurkdjian P, Bouvet P, Haeghebaert S, Filliol I, Loirat C, Decludt B, Minh NN, Vaillant V, de Valk H (2008) Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 Shiga toxin-producing Escherichia coli infections in France, 1996–2006. Pediatr Infect Dis J 27:595–601CrossRefPubMed
3.
go back to reference Trachtman H, Austin C, Lewinski M, Stahl RA (2012) Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 8:658–669CrossRefPubMed Trachtman H, Austin C, Lewinski M, Stahl RA (2012) Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 8:658–669CrossRefPubMed
4.
go back to reference Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF (2003) Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 290:1360–1370CrossRefPubMed Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF (2003) Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 290:1360–1370CrossRefPubMed
5.
go back to reference Ferdous M, Zhou K, de Boer RF, Friedrich AW, Kooistra-Smid AM, Rossen JW (2015) Comprehensive characterization of Escherichia coli O104:H4 isolated from patients in the Netherlands. Front Microbiol 6:1348CrossRefPubMedPubMedCentral Ferdous M, Zhou K, de Boer RF, Friedrich AW, Kooistra-Smid AM, Rossen JW (2015) Comprehensive characterization of Escherichia coli O104:H4 isolated from patients in the Netherlands. Front Microbiol 6:1348CrossRefPubMedPubMedCentral
6.
go back to reference Espie E, Mariani-Kurkdjian P, Grimont F, Pihier N, Vaillant V, Francart S, Capek I, de Valk H, Vernozy-Rozand C (2006) Shiga toxin-producing Escherichia coli O26 infection and unpasteurised cows cheese. Abstract presented of the 6th International Symposium on Shigatoxin (verocytotoxin)-Producing Escherichia coli Infections. Melbourne, Australia; October 30–November 1, 2006 Espie E, Mariani-Kurkdjian P, Grimont F, Pihier N, Vaillant V, Francart S, Capek I, de Valk H, Vernozy-Rozand C (2006) Shiga toxin-producing Escherichia coli O26 infection and unpasteurised cows cheese. Abstract presented of the 6th International Symposium on Shigatoxin (verocytotoxin)-Producing Escherichia coli Infections. Melbourne, Australia; October 30–November 1, 2006
7.
go back to reference Mariani-Kurkdjian P, Lemaitre C, Bidet P, Perez D, Boggini L, Kwon T, Bonacorsi S (2014) Haemolytic-uraemic syndrome with bacteraemia caused by a new hybrid Escherichia coli pathotype. New Microbes New Infect 2:127–131CrossRefPubMedPubMedCentral Mariani-Kurkdjian P, Lemaitre C, Bidet P, Perez D, Boggini L, Kwon T, Bonacorsi S (2014) Haemolytic-uraemic syndrome with bacteraemia caused by a new hybrid Escherichia coli pathotype. New Microbes New Infect 2:127–131CrossRefPubMedPubMedCentral
8.
go back to reference Soysal N, Mariani-Kurkdjian P, Smail Y, Liguori S, Gouali M, Loukiadis E, Fach P, Bruyand M, Blanco J, Bidet P, Bonacorsi S (2016) Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge. Emerg Infect Dis 22:1604–1612CrossRefPubMedPubMedCentral Soysal N, Mariani-Kurkdjian P, Smail Y, Liguori S, Gouali M, Loukiadis E, Fach P, Bruyand M, Blanco J, Bidet P, Bonacorsi S (2016) Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge. Emerg Infect Dis 22:1604–1612CrossRefPubMedPubMedCentral
9.
go back to reference de Boer RF, Ferdous M, Ott A, Scheper HR, Wisselink GJ, Heck ME, Rossen JW, Kooistra-Smid AM (2015) Assessing the public health risk of Shiga toxin-producing Escherichia coli by use of a rapid diagnostic screening algorithm. J Clin Microbiol 53:1588–1598CrossRefPubMedPubMedCentral de Boer RF, Ferdous M, Ott A, Scheper HR, Wisselink GJ, Heck ME, Rossen JW, Kooistra-Smid AM (2015) Assessing the public health risk of Shiga toxin-producing Escherichia coli by use of a rapid diagnostic screening algorithm. J Clin Microbiol 53:1588–1598CrossRefPubMedPubMedCentral
10.
go back to reference Bielaszewska M, Friedrich AW, Aldick T, Schurk-Bulgrin R, Karch H (2006) Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clin Infect Dis 43:1160–1167CrossRefPubMed Bielaszewska M, Friedrich AW, Aldick T, Schurk-Bulgrin R, Karch H (2006) Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clin Infect Dis 43:1160–1167CrossRefPubMed
11.
go back to reference Geerdink LM, Westra D, van Wijk JA, Dorresteijn EM, Lilien MR, Davin JC, Komhoff M, Van Hoeck K, van der Vlugt A, van den Heuvel LP, van de Kar NC (2012) Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 27:1283–1291CrossRefPubMedPubMedCentral Geerdink LM, Westra D, van Wijk JA, Dorresteijn EM, Lilien MR, Davin JC, Komhoff M, Van Hoeck K, van der Vlugt A, van den Heuvel LP, van de Kar NC (2012) Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 27:1283–1291CrossRefPubMedPubMedCentral
12.
go back to reference Wijnsma KL, van Bommel SA, van der Velden T, Volokhina E, Schreuder MF, van den Heuvel LP, van de Kar NC (2016) Fecal diagnostics in combination with serology: best test to establish STEC-HUS. Pediatr Nephrol 31:2163–2170CrossRefPubMedPubMedCentral Wijnsma KL, van Bommel SA, van der Velden T, Volokhina E, Schreuder MF, van den Heuvel LP, van de Kar NC (2016) Fecal diagnostics in combination with serology: best test to establish STEC-HUS. Pediatr Nephrol 31:2163–2170CrossRefPubMedPubMedCentral
13.
go back to reference Agger M, Scheutz F, Villumsen S, Molbak K, Petersen AM (2015) Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposal. J Antimicrob Chemother 70:2440–2446CrossRefPubMed Agger M, Scheutz F, Villumsen S, Molbak K, Petersen AM (2015) Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposal. J Antimicrob Chemother 70:2440–2446CrossRefPubMed
14.
go back to reference Legendre CM, Licht C, Loirat C (2013) Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 369:1379–1380PubMed Legendre CM, Licht C, Loirat C (2013) Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 369:1379–1380PubMed
15.
go back to reference Pape L, Hartmann H, Bange FC, Suerbaum S, Bueltmann E, Ahlenstiel-Grunow T (2015) Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine (Baltimore) 94, e1000CrossRefPubMed Pape L, Hartmann H, Bange FC, Suerbaum S, Bueltmann E, Ahlenstiel-Grunow T (2015) Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine (Baltimore) 94, e1000CrossRefPubMed
16.
go back to reference Hayes W, Tschumi S, Ling SC, Feber J, Kirschfink M, Licht C (2015) Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol 30:775–781CrossRefPubMed Hayes W, Tschumi S, Ling SC, Feber J, Kirschfink M, Licht C (2015) Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol 30:775–781CrossRefPubMed
Metadata
Title
Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2
Authors
Kioa L. Wijnsma
Anne M. Schijvens
John W. A. Rossen
A. M. D. (Mirjam) Kooistra-Smid
Michiel F. Schreuder
Nicole C. A. J. van de Kar
Publication date
01-07-2017
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 7/2017
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-017-3642-3

Other articles of this Issue 7/2017

Pediatric Nephrology 7/2017 Go to the issue